Alessandro Lucchesi: Mechanistic Biology as the Engine of Next-Generation Therapies
Alessandro Lucchesi, Consultant Hematologist at Romagna Scientific Institute for the Study and Treatment of Cancer (I.R.S.T.) Ltd., shared a post on LinkedIn:
“Stockholm, EHA 2026.
The biological foundations underpinning new therapies are, to my mind, of the utmost importance: to construct paradigms is to alter trajectories, and to look beyond appearances.
It is not only the clone that matters in myelofibrosis, just as it is not only the antibodies in ITP and wAIHA.
Inflammation as a primary driver of chronic disease, the dysregulation of tolerance, and dysfunctional cellular metabolism have long been at the centre of my work – and they are precisely what allow us to read mechanisms like XPO-1 dependence, or BTK as an integrator of immune activation, not as isolated targets but as expressions of a deeper biology.
I am grateful to Menarini Stemline and Sanofi for the platform to develop these arguments at the MF and ITP/wAIHA symposia, and to IRCCS Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’ – IRST Srl for the scientific home that makes such work possible.
The foundations are where the next therapies will be decided. That is the conversation I want to keep having.
Disclosure: invited speaker at the Menarini Stemline and Sanofi satellite symposia referenced here.”
Stay updated with Hemostasis Today.
-
Jun 17, 2026, 11:45Advancing Patient-Centred Innovation in Thalassaemia Care at EHA2026 – TIF
-
Jun 17, 2026, 11:23Gabriela Hobbs: Emerging Myelofibrosis Therapies at EHA 2026
-
Jun 17, 2026, 09:54Shadi Tabibian: Improving Outcomes Through Accurate VWD Subclassification
-
Jun 17, 2026, 09:47Nihal Mesmoudi: Inspired by Scientific Excellence at ICMES 2026
-
Jun 17, 2026, 09:26Nicolas Gendron: Join the Conversation on Antithrombotic Stewardship at ISTH 2026
-
Jun 17, 2026, 09:19Natalia Schütz: Translating Scientific Advances into Better Patient Outcomes
-
Jun 17, 2026, 05:21Finn Guo: Exploring Payment Mechanisms for Innovative Hemophilia Therapies
-
Jun 17, 2026, 04:59Wolfgang Miesbach: One-Time CRISPR Therapy Reduces Hereditary Angioedema Attacks by 87%
-
Jun 17, 2026, 04:47Ganesh Mohan: Celebrating the Heroes of Healthcare on World Blood Donor Day 2026